



ASX ANNOUNCEMENT

Actinogen Medical to present at BIO International 2018

- Actinogen Medical to present at BIO International Convention, the world's largest and most prestigious biotechnology convention held in Boston USA, in early June.
- BIO International attracts the leading organisations in global biotech and facilitates networking on new opportunities and partnerships.
- BIO 2018 is the ideal forum to showcase Actinogen and Xanamem - including the excellent progress made with XanADu, the recently announced Interim Analysis outcome, the \$17M capital raising and the broader development plans for Xanamem that flow from it.

Sydney 31 May 2018. Actinogen Medical (ASX: ACW) is pleased to announce that the Company's CEO Dr. Bill Ketelbey is leading the Actinogen team, and presenting, at the BIO International Convention in Boston USA, 4-7 June 2018.

Dr Ketelbey will meet with global biotech industry leaders and prospective future business partners. This follows on from the pleasing progress made with XanADu, the Company's Phase II clinical trial of Xanamem in Alzheimer's disease, with the positive recommendation from the Data Safety Monitoring Board (DSMB) following the Interim Analysis, to continue XanADu without modification. XanADu currently has 103 of the 174 patients enrolled – 60% of the total. Concurrent with the positive Interim Analysis recommendation, the Company secured a \$15M investment by three leading institutional investors, led by leading US specialist biotech investor Biotechnology Value Fund L.P. (BVF), providing strong endorsement of the Company and its added development plans for Xanamem. Additionally, a Share Purchase Plan has been launched to raise up to a further \$2M.

The BIO International Convention, hosted by the Biotechnology Innovation Organisation (BIO), is the largest global convention for the biotechnology industry and attracts the leading organisations in biotech to network on new opportunities and potential partnerships.

Participation at BIO International provides Actinogen unparalleled networking opportunities to showcase the Company and the quality research that supports Xanamem's development. The BIO International presentation is attached.

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

Media Enquires

Zena Chamas
Media & Capital Partners
M: +61 434 153 055
E: zena.chamas@mcpartners.com.au

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.